Evidence map›Paper›PMID 41524175›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Elemene Augments the Effects of Anti-PD-1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR-130a-5p/SPP/MHC-I Axis.

Menglan Wang, Mengqing Sun, Heng Dong, Xiaoting Zhang, Jingbo Zhang, Zhengguo Zhang, Mengjie Ni, Lina Li, Yunxin Pei, Xiaoyu Chen and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Menglan WangZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Mengqing SunZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Heng DongZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Xiaoting ZhangZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Jingbo ZhangZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Zhengguo ZhangZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Mengjie NiZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Lina LiZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Yunxin PeiZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Xiaoyu ChenZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Qian LiZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Fangtian BuZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Jiacheng HuangDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, NHC Key Laboratory of Combined Multi-organ Transplantation, Key Laboratory of Organ Transplantation, Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Science (2019RU019), Hangzhou, 310003, China.
Liangyu JiangZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Zhuting FangDepartment of Oncology and Vascular Intervention, Clinical Oncology School of Fujian Medical University, Fujan Cancer Hospital, Fuzhou, Fujian, 350001, China.
Xuliang ChenKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, China.
Jianxiang ChenZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.ORCID https://orcid.org/0000-0002-8193-191X
Yiting QiaoDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, NHC Key Laboratory of Combined Multi-organ Transplantation, Key Laboratory of Organ Transplantation, Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Science (2019RU019), Hangzhou, 310003, China.
Tian XieZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.ORCID https://orcid.org/0000-0003-4368-760X

Funding

Hangzhou Normal University Dengfeng Project - Clinical Medicine Revitalization Plan Jiande Hospital Special Project LCYXZXJH003National Administration of Traditional Chinese Medicine & Zhejiang Province GZY-ZJ-KJ-24045National Natural Science Foundation of China 82373888National Natural Science Foundation of China 82574448Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2023-PT320-02Postgraduate research innovation project of Hangzhou Normal University 2022HSDYJSKY015Start-up Grant of Hangzhou Normal University 4275C50222204072Traditional Chinese Medicine Science and Technology Project of Zhejiang Province 2023ZL486
6 · The paper itself

Abstract

Immune checkpoint inhibitors, particularly PD-1 inhibitors, constitute the cornerstone of first-line treatment for hepatocellular carcinoma (HCC). However, suboptimal overall response rates persist alongside dual challenges: immune-related toxicities and immunosuppressive tumor microenvironment. Combination therapies represent a pivotal strategy to overcome these limitations. In recent years, traditional Chinese medicine has gained significant attention. Elemene, a small-molecule compound derived from Curcuma wenyujin, has garnered attention for its immunomodulatory potential and demonstrates clinical efficacy in combination therapies. Nevertheless, its synergistic mechanisms with immunotherapy remain incompletely characterized. This study demonstrates for the first time that elemene modulates the miR-130a-5p/SPP/MHC-I axis, resulting in an enhanced diversity and abundance of antigen/MHC-I complexes on the surface of HCC cells. This mechanism promotes the recognition and elimination of HCC cells by cytotoxic T lymphocytes, thereby augmenting the antitumor immune efficacy of PD-1. Moreover, the functional significance of the miR-130a-5p/SPP/MHC-I axis in modulating the tumor immune microenvironment is systematically validated through in vitro and in vivo HCC models, as well as in clinical patient specimens. These findings underscore the potential of combining elemene with anti-PD-1 therapy as a safe and effective treatment strategy for HCC, offering significant translational promise for improving patient outcomes.

Indexed as

Carcinoma, HepatocellularImmune Checkpoint InhibitorsImmunotherapyLiver NeoplasmsMicroRNAsSesquiterpenesAnimalsCell Line, TumorHumansMiceProgrammed Cell Death 1 ReceptorTumor MicroenvironmentelemeneImmune Checkpoint InhibitorsMicroRNAsMIRN130 microRNA, humanProgrammed Cell Death 1 ReceptorSesquiterpenesantigen presentationcytotoxic T lymphocytesimmune checkpoint inhibitorsorganoidstumor immune microenvironment

Identifiers

PMID41524175
PMCPMC12931222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.